Juvenile Idiopathic arthritis (JIA) Market

Key Highlights

• JIA is an umbrella term for a heterogeneous group of conditions classified according to ILAR. This classification includes seven categories of JIA, which mainly fall into two types according to differences in clinical symptoms and pathophysiology, namely systemic JIA (sJIA) and the other six JIA categories. The latter consist of oligoarthritis, rheumatoid factor-negative polyarthritis, rheumatoid factor-positive polyarthritis, psoriatic arthritis, enthesitis-related arthritis, and undifferentiated arthritis, and are often considered as “articular-type JIA” (non-sJIA) in clinical practice.
• Therapeutic management in JIA is focused on achieving rapid and sustained disease remission, or at a minimum, maintaining low disease activity, by effectively controlling inflammation and associated symptoms. Current treatment strategies span a step-wise and individualized approach, utilizing nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, conventional synthetic DMARDs (csDMARDs), biologic DMARDs (bDMARDs), and targeted small-molecule therapies such as Janus kinase inhibitors (JAK inhibitors).
• The current JIA treatment landscape includes a broad range of marketed targeted therapies spanning multiple mechanisms of action, developed by leading pharmaceutical companies, including AbbVie (RINVOQ), Sanofi/Regeneron (KEVZARA), Johnson & Johnson (TREMFYA), Novartis (COSENTYX and ILARIS), UCB (CIMZIA), Bristol Myers Squibb (ORENCIA), Johnson & Johnson/Merck (SIMPONI ARIA), Eli Lilly (OLUMIANT and TALTZ), Swedish Orphan Biovitrum (KINERET), and Pfizer (XELJANZ), reflecting continued innovation and competition in the JIA therapeutic space.
• Whereas the emerging JIA pipeline remains relatively limited, a small number of late- and mid-stage assets such as SOTYKTU (deucravacitinib), BIMZELX (bimekizumab), MAS825, and filgotinib are being evaluated.
• In the 7MM, the United States recorded the highest number of prevalent JIA cases in 2025, with this burden expected to continue increasing through 2036. Emerging analyses from large claims databases indicate a notable uptick in diagnoses, reflecting growing awareness and better detection of the disease.
• The JIA market in the 7MM is estimated to be around USD 2,300 million in 2025 and is projected to grow during the forecast period (2026–2036).
• The total market size of JIA in the United States was approximately USD 2,150 million in 2025 and is projected to increase during the forecast period.

DelveInsight's ‘Juvenile Idiopathic Arthritis (JIA) – Market Insights, Epidemiology and Market Forecast – 2036’ report delivers an in-depth understanding of the JIA, historical and forecasted epidemiology, as well as the mitochondrial myopathies market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The JIA market report provides emerging drugs, market share and uptake of individual therapies, and current and forecasted 7MM JIA market size from 2022 to 2036. The report also outlines key unmet medical needs and maps the competitive and clinical landscape to identify high-value opportunities, offering a clear view of the future growth potential of the JIA market.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Juvenile Idiopathic Arthritis (JIA) Understanding and Treatment Algorithm

Juvenile Idiopathic Arthritis (JIA) Overview

Juvenile idiopathic arthritis (JIA) is the most common chronic inflammatory arthritis in children, caused by immune-mediated inflammation of the synovium that leads to persistent joint pain, swelling, stiffness, and effusions, with potential cartilage and bone damage, extra-articular involvement such as uveitis, and impaired growth if untreated; early diagnosis and appropriate therapy can significantly improve long-term outcomes. JIA includes several subtypes characterized by arthritis lasting at least six weeks: oligoarticular JIA, the most common and typically mildest form, affecting four or fewer joints and carrying a higher uveitis risk in young ANA-positive girls; polyarticular JIA, involving five or more joints and occurring as RF-negative or RF-positive disease, the latter resembling adult rheumatoid arthritis; enthesitis-related arthritis, marked by arthritis and enthesitis, more common in boys and associated with axial involvement; psoriatic JIA, combining inflammatory arthritis with psoriasis or related features; systemic JIA, a distinct whole-body inflammatory disease with fevers, rash, and possible organ involvement affecting both sexes equally; and undifferentiated arthritis, which does not fit a single category. Across subtypes, disease severity and course vary widely and may include joint inflammation, reduced mobility, systemic symptoms, and growth-related complications.

Juvenile Idiopathic Arthritis (JIA) Diagnosis

Juvenile idiopathic arthritis (JIA) has no single definitive diagnostic or prognostic test, and diagnosis is based on a combination of clinical features, laboratory findings, imaging, and exclusion of other causes of pediatric arthritis, with persistent joint inflammation lasting at least six weeks in children under 16 years raising suspicion. Initial evaluation typically includes CBC, ESR, and CRP to assess inflammation; ANA testing to help identify oligoarticular and some polyarticular or psoriatic subtypes and stratify uveitis risk; RF and anti-CCP antibodies to identify a more aggressive, RA-like polyarticular course; and HLA-B27 to support a diagnosis of enthesitis-related arthritis. Additional laboratory tests, such as ferritin, fibrinogen, AST, and triglycerides, are used when macrophage activation syndrome is suspected. Imaging supports diagnosis and monitoring, with plain radiographs assessing structural damage, ultrasound detecting active synovitis and effusions, and MRI serving as the gold standard for identifying early synovitis, bone marrow edema, and erosions. Classification of JIA subtypes follows ILAR criteria based on clinical presentation within the first six months, distinguishing oligoarticular, polyarticular (RF-negative or RF-positive), systemic JIA, psoriatic arthritis, enthesitis-related arthritis, and undifferentiated disease. 

Further details are provided in the report.

Juvenile Idiopathic Arthritis (JIA) Treatment

The primary goals of juvenile idiopathic arthritis (JIA) treatment are to control inflammation, relieve pain and stiffness, prevent joint and organ damage, preserve function, support normal physical, emotional, and social development, achieve remission or minimal disease activity, and enable full participation in daily activities. Management is multidisciplinary and centers on pharmacologic therapy, with NSAIDs used for symptomatic relief, corticosteroids reserved for short-term control or localized inflammation, and disease-modifying antirheumatic drugs (DMARDs), most commonly methotrexate, used to suppress immune activity and prevent long-term joint damage. Biologic agents targeting specific inflammatory pathways, including TNF-a, IL-1, and IL-6, are widely used to achieve sustained disease control, often in combination with DMARDs, though they carry an increased risk of infection. Physical and occupational therapy are integral to care, focusing on pain reduction, maintenance of joint mobility, muscle strengthening, and injury prevention through individualized exercise programs and supportive devices, while surgical intervention is rarely required and reserved for severe, refractory disease to improve function and quality of life.

Further details related to country-based variations are provided in the report.

Juvenile Idiopathic Arthritis (JIA) Epidemiology

As the market is derived using a patient-based model, the JIA epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of JIA, subtype-specific prevalent cases of JIA, gender-specific prevalent cases of JIA, and treatment-eligible cases of JIA in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2022 to 2036.

• According to DelveInsight analysis, the total prevalent cases of JIA in the 7MM were approximately 141,800      in 2025 and are projected to increase to around 173,000 by 2036 over the forecast period, reflecting a CAGR of 1.8%.
• In the 7MM, the United States recorded the highest number of prevalent JIA cases in 2025, with this burden expected to continue increasing through 2036.
• In the US, approximately 33,900 diagnosed JIA patients in 2025 were male, whereas 66% female. This sex difference is attributed to the higher susceptibility of females to developing JIA, whereas the onset in males tends to occur later.
• Among the EU4 and the UK, Germany accounted for the highest number of JIA cases, followed by the UK, whereas France accounted for the lowest number of cases in 2025.
• In 2025, the United States recorded approximately 33,000 cases of oligoarticular JIA and 29,000 cases of polyarticular JIA (RF-positive and RF-negative combined), and both subtypes are expected to increase over the forecast period.
• In Japan, JIA is much more common among females. Studies indicate a higher prevalence of disease burden in females compared to males. In 2025, the prevalent cases of JIA were higher in females, accounting for 65% of the total cases in Japan, while males represented 35% of the affected population.

Juvenile Idiopathic Arthritis (JIA) Drug Chapters

The JIA drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I–III clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the JIA  treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the JIA therapeutics market.

Marketed Therapies

Upadacitinib (RINVOQ): AbbVie

Upadacitinib, developed by AbbVie, is an oral, once-daily selective JAK inhibitor approved for the treatment of pJIA in pediatric patients when one or more conventional or biologic DMARDs are inadequate or not tolerated. By inhibiting JAK-mediated intracellular signaling pathways involved in immune activation and inflammation, upadacitinib helps reduce joint inflammation, pain, and disease activity associated with pJIA.

• In September 2025, AbbVie submitted a filing in Japan for label expansion of upadacitinib for an additional indication of pJIA inadequately controlled with existing treatments, indicating work toward broader global availability for this indication beyond the US.
• In April 2024, the US FDA granted approval to upadacitinib for the treatment of children 2 years of age and older with active pJIA.

Emerging Therapies

Deucravacitinib (SOTYKTU): Bristol-Myers Squibb

It is an orally administered, highly selective TYK2 inhibitor with a novel allosteric mechanism, representing a new class of small-molecule therapies. It is the first selective TYK2 inhibitor to be evaluated in clinical studies across multiple immune-mediated diseases. Developed by Bristol Myers Squibb, it is designed to specifically target TYK2, thereby inhibiting signaling pathways mediated by interleukin (IL)-23, IL-12, and type I interferons (IFNs), which play key roles in the pathogenesis of immune-mediated disorders. High selectivity is achieved through binding to the regulatory domain of TYK2, resulting in allosteric inhibition of TYK2 activity and downstream signaling. At physiologically relevant and therapeutic concentrations, it selectively inhibits TYK2 without inhibiting JAK1, JAK2, or JAK3.

• In July 2025, the FDA accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis. The FDA has assigned a PDUFA goal date of March 6, 2026.

Drug Class Insights

The JIA market comprises targeted small molecules and biologics, and T-cell co-stimulation modulators alongside conventional and supportive therapies, each addressing distinct immunologic pathways and inflammatory mechanisms underlying JIA.

Targeted small molecules: Upadacitinib (RINVOQ) is a selective JAK1 inhibitor that delivers robust anti-inflammatory efficacy in JIA by modulating key cytokine signaling pathways, validating the clinical and commercial potential of oral, mechanism-driven therapies in pediatric autoimmune disease.

Biologics: Sarilumab (KEVZARA) is an interleukin-6 receptor blocking monoclonal antibody that targets a central inflammatory pathway in JIA, reducing systemic and joint inflammation and supporting the role of cytokine-specific biologics as effective disease-modifying therapies in pediatric autoimmune disease.

T-cell co-stimulation modulators: Abatacept (ORENCIA), a recombinant fusion protein from Bristol-Myers Squibb, inhibits CD80/CD86-CD28 signaling to modulate T-cell activation. It is administered subcutaneously or by intravenous infusion and is approved for pediatric JIA and psoriatic arthritis, providing targeted immune control and durable disease management.

Market & Strategic Analysis:

Biologics and targeted small molecules together define the core innovation landscape in JIA, with biologics already well established clinically and commercially, while oral small molecules are driving next-generation pipeline growth.

The market continues to face high unmet need across refractory and severe JIA subtypes, creating opportunities for first-in-class therapies, line extensions, and broader label expansions.

JIA Market Outlook

The JIA market is undergoing a significant shift after years of dependence on conventional immunosuppression and stepwise empiric treatment. The approvals and expanding use of targeted therapies such as upadacitinib (RINVOQ) and sarilumab (KEVZARA) mark a transition toward mechanism-driven, disease-modifying management in JIA. These advances validate cytokine- and pathway-specific approaches, reinforce regulatory and clinical confidence in targeted immunomodulation, and are reshaping the competitive landscape by expanding therapeutic options and accelerating innovation across the JIA pipeline.

Upadacitinib (RINVOQ), as an advanced targeted JAK inhibitor, demonstrates meaningful clinical benefit in controlling inflammation and improving disease outcomes in JIA, reinforcing the role of precision therapies in pediatric rheumatology. Its regulatory success highlights increasing flexibility in evidence standards for pediatric and rare inflammatory conditions, strengthens confidence in the JIA therapeutics market, and is expected to catalyze further investment and R&D across the JIA treatment pipeline.

With the advancement of targeted and biologic therapies such as deucravacitinib, bimekizumab, and MAS825, the JIA treatment landscape is evolving in a manner similar to other immune-mediated and rare inflammatory diseases, where early approvals often catalyze broader therapeutic expansion. The United States continues to represent the largest JIA market, driven by higher diagnosis rates, earlier biologic adoption, strong patient and physician awareness, and more rapid uptake of innovative therapies compared with the EU4, the UK, and Japan.

Overall, the launch of first-in-class therapies, improved genetic testing, and rising disease awareness are expected to drive steady growth in the 7MM JIA market from 2022–2036, with strong commercial implications for both marketed products and emerging pipelines.

The JIA market is evolving as treatment focus shifts from broad-spectrum biologics to more targeted therapies, with JAK inhibitors and IL-targeted agents driving adoption due to their favorable efficacy, safety, and expanded pediatric indications.

• Regional market dynamics show the US leading in revenue, while Japan and EU markets demonstrate steady growth, reflecting increasing diagnosis rates, broader pediatric access, and rising adoption of novel mechanisms.
• According to the estimates, the largest market size of JIA is expected to be from the United States, i.e., USD 3,550 million by 2036.
• Among EU4 and the UK, Germany will capture the maximum revenue share, followed by Italy and the UK by 2036.
• In Japan, the maximum market share is expected to be captured by adalimumab in 2036.

Key Updates

• The FDA has accepted for review the supplemental New Drug Application (sNDA) for deucravacitinib for the treatment of adults with active psoriatic arthritis. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.
• Sobi announced that it has decided to initiate two clinical programs with Anakinra in North America, intending to evaluate two new potential indications for KINERET, where a significant need for alternative treatment options exists: acute gout and Still’s disease.

Further details will be provided in the report….

Juvenile Idiopathic Arthritis (JIA) Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026–2036). The analysis covers the JIA market's uptake by drugs, patient uptake by therapy, and sales of each drug.

The uptake of therapies in JIA is expected to show a clear differentiation between highly targeted biologics and newer mechanism-specific small molecules vs. broader immunomodulators and conventional DMARDs. Recently approved therapies such as upadacitinib (RINVOQ) and sarilumab (KEVZARA) are expected to demonstrate the fastest and most concentrated uptake, driven by clearly defined patient populations (e.g., pJIA), first-mover or novel mechanism advantage, strong clinical need in refractory disease, and early preference among pediatric rheumatology specialists. Their adoption is accelerated by the limitations of conventional therapies in achieving durable remission and the high value placed on improved functional outcomes and quality of life in children with persistent disease activity.

In comparison, next-generation targeted therapies such as other JAK inhibitors (e.g., baricitinib) and emerging cytokine modulators (e.g., IL-17 inhibitors) are expected to follow a more gradual but steady uptake curve, reflecting their broader potential across clinically heterogeneous JIA subtypes, ongoing clinical development, and adoption following integration into treatment algorithms after established therapies.

Further detailed analysis of emerging therapies' drug uptake in the report…

Market Access and Reimbursement Key Developments in 2025

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Market Access and Reimbursement of JIA

The United States

Pricing Landscape and Cost Benchmarking

The pricing landscape for therapies in JIA reflects orphan-disease economics, subtype-specific clinical differentiation (systemic vs. polyarticular and other categories), and payer value assessments. This section summarizes the cost of approved treatments, benchmarks expected pricing for emerging therapies, and analyzes how pricing influences market access, adherence, and long-term uptake.

Pricing of Approved Therapies

Approved therapies generally adopt premium WAC pricing, supported by high unmet need and limited competition. Annual treatment cost, dosing intensity, and administration setting (oral vs parenteral) shape payer coverage and patient affordability.

Upadacitinib is administered at a dose of 15 mg once daily for patients weighing =30 kg. The list price (WAC) for a 30-day supply is USD 6,752.77, translating to an estimated annual therapy cost of approximately USD 74,299.

Sarilumab is administered as a subcutaneous injection at a dose of 200 mg once every two weeks. The 200 mg formulation is priced at USD 4,774.62 for a two-unit pack, resulting in an estimated annual therapy cost of approximately USD 55,569.

Benchmarking Emerging Therapies

The estimated cost assumptions for the emerging drugs have been considered based on the competitive pricing of the therapies currently available.

Emerging target-specific therapies show differentiated cost expectations:

MAS825 has been benchmarked against Canakinumab, as both are interleukin inhibitors developed by Novartis. The pricing strategy for MAS825 has been aligned closely with Canakinumab, reflecting its comparable mechanism of action and therapeutic value.

Overall, pricing will significantly influence early adoption, competitive positioning, and long-term penetration across the 7MM JIA market.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the JIA emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and prevalence patterns in rare mitochondrial disorders, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 6+ KOLs in the 7MM. Centers such as the University of North Carolina at Chapel Hill, Berlin Institute of Health at Charité, and the University of Nottingham, etc. were contacted. Their opinion helps understand and validate current and emerging JIA therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in JIA.

Qualitative Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of JIA, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst’s discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The analyst analyzes multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial’s primary and secondary outcome measures are evaluated.

Further, the therapies’ safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of JIA, explaining its causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the JIA market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM JIA market.

Juvenile Idiopathic Arthritis (JIA) Report Insights

• Patient population
• Therapeutic approaches
• JIA pipeline analysis
• JIA market size and trends
• Existing and future market opportunity

Juvenile Idiopathic Arthritis (JIA) Report Key Strengths

• Ten-year forecast
• 7MM coverage
• Mitochondrial myopathies epidemiology segmentation
• Key cross competition
• Highly analyzed market
• Drug uptake
• Peak Shares

Juvenile Idiopathic Arthritis (JIA) Report Assessment

• Current treatment practices
• Unmet needs
• Pipeline product profiles
• Market attractiveness
• Qualitative analysis (SWOT and conjoint analysis)

FAQs

Market Insights

• What was the JIA market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of JIA?
• What are the disease risks, burdens, and unmet needs of JIA? What will be the growth opportunities across the 7MM concerning the patient population with JIA?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of JIA? What are the current guidelines for treating JIA in the US, Europe, and Japan?

Reasons to Buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the JIA market.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.